RankAlpha logo
Back to Rankings

NBIX

Neurocrine BiosciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The bull case is that NBIX is still fundamentally a commercial-execution story with unusually strong primary-source support: Q1 2026 product sales grew sharply, INGREZZA guidance was reaffirmed, CRENESSITY showed meaningful early demand and reimbursement traction, and the Soleno acquisition is now closed, reducing one major event risk.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
CRENESSITY is early in launch, so reimbursement durability and commercial persistence remain important to monitor. [#SEC-8K-2026-05-05]
Momentum
50
Value
62
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $188.00 · Bull $205.00 · Bear $154.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-03 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $199.37
Why
Momentum50 · Δ7d -18.0
Value62 · Δ7d +0.0
Sentiment53 · Δ7d +0.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
50
26% active weight
Current posture
7d trendFlat
Δ7d
-18.0
Δ21d
-36.0
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.1
Sentiment
53
34% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-2.0
Why this grade

Composite grade B. Momentum 49.6 / Value 62.4 / Sentiment 53.3

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$17.18B
Beta
0.31
Shares Out
100.55M
P/E (TTM)
32.5
P/S (TTM)
5.05
P/FCF (TTM)
22.86
Rev YoY
+42.2%
EPS YoY
+2382.4%
Gross Margin
+98.2%
Op Margin
+20.5%
Net Debt
-$1.01B
Current Ratio
2.93
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology